<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573312</url>
  </required_header>
  <id_info>
    <org_study_id>10-0074</org_study_id>
    <secondary_id>N01AI80007C</secondary_id>
    <secondary_id>VTEU 02-2011</secondary_id>
    <nct_id>NCT01573312</nct_id>
  </id_info>
  <brief_title>H5N1 Vaccination With and Without AS03: Systems Biology Analysis</brief_title>
  <official_title>A Randomized, Double-Blinded, Controlled, Phase I Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of Intramuscular Subvirion Inactivated Monovalent Influenza A/H5N1 Virus Vaccine Administered With and Without AS03 Adjuvant: Standard &amp; Systems Biology Analyses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      This is a single center, randomized, double-blinded, controlled, Phase I, small targeted&#xD;
      prospective study in healthy male and non-pregnant female subjects, 18 to 49 years old,&#xD;
      inclusive, designed to determine the safety, reactogenicity, and immunogenicity of an&#xD;
      intramuscular subvirion inactivated monovalent influenza A/H5N1 (HA of A/Indonesia/05/2005)&#xD;
      virus vaccine manufactured by Sanofi Pasteur administered at 3.75 mcg per dose given with or&#xD;
      without AS03 adjuvant manufactured by GSK. In the study, each subject will receive two doses&#xD;
      administered 28 days apart. This study will use a systems biology approach to assess the&#xD;
      human early gene and protein signatures expressed at Days 1, 3, 7, and 28 after the first&#xD;
      vaccination. The systems data will be integrated with immunogenicity and reactogenicity data&#xD;
      to develop a systems model of the human immune response to A/H5N1 vaccine with or without&#xD;
      AS03 adjuvant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long term goals of this project are to identify RNA or protein biomarkers within 1 to 7&#xD;
      days after vaccination in peripheral blood that will predict a successful immune response and&#xD;
      protection against disease. Adjuvants are used to boost the response of vaccines by&#xD;
      stimulating the innate immune response. However, the exact mechanism and safety of adjuvants&#xD;
      is still debated. Systems biology is the study of complex biological processes as integrated&#xD;
      systems with many interacting components. The goal of systems biology is to make biology more&#xD;
      predictive. This proposal will use a systems biology approach to identify successful&#xD;
      immunization biomarkers. The study will use fresh blood samples and patient data collected in&#xD;
      the proposed VTEU-funded study. At selected time points, volunteers' blood samples will be&#xD;
      collected and immediately processed. Using these specimens, we will identify and quantify&#xD;
      changes in the whole transcriptome and proteome of the major immune cells to identify and&#xD;
      quantify changes in gene expression. We will integrate the changes in gene expression with&#xD;
      the changes in the immune cells response. We will use mathematical modeling of the&#xD;
      accumulated data to identify RNA or protein biomarkers that significantly correlate with the&#xD;
      observed serum hemagglutination inhibition assay (HAI) response,cytokine/chemokine response,&#xD;
      and cell mediated immunity (CMI) responses. Ultimately, the predictive biomarkers will be the&#xD;
      foundation for a simple, rapid, inexpensive test to quickly show protection against a&#xD;
      pathogen or foreign agent after vaccination. This is a single center, randomized,&#xD;
      double-blinded, controlled, Phase I, small targeted prospective study in healthy male and&#xD;
      non-pregnant female subjects, 18 to 49 years old, inclusive, designed to determine the&#xD;
      safety, reactogenicity, and immunogenicity of an intramuscular subvirion inactivated&#xD;
      monovalent influenza A/H5N1 (HA of A/Indonesia/05/2005) virus vaccine manufactured by Sanofi&#xD;
      Pasteur administered at 3.75 mcg per dose given with or without AS03 adjuvant manufactured by&#xD;
      GSK. In the study, each subject will receive two doses administered 28 days apart.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2012</start_date>
  <completion_date type="Actual">January 2, 2014</completion_date>
  <primary_completion_date type="Actual">January 2, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GMT of neutralizing antibody, proportion of subjects achieving a serum neutralizing antibody titer of 1:40 or greater, and frequency of 4-fold or greater increases of neutralizing antibodies in each group against the subvirion inactivated A/H5N1 virus</measure>
    <time_frame>Approximately Days:1, 3, 7 and 28, after receipt of the first dose of vaccine.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of vaccine associated serious adverse events (SAEs) from the time of first vaccination through 13 months after the first vaccination.</measure>
    <time_frame>Day 0 through 13 months after receipt of the first dose of vaccine.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of solicited local and systemic reactogenicity in the 8 days (Days 0 through Day 7) after each vaccination.</measure>
    <time_frame>Day 0 through Day 7 after each dose of vaccine</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean titer (GMT) of the hemagglutination inhibition assay (HAI) antibody, proportion of subjects achieving serum HAI antibody titer 1:40 or greater, &amp; frequency of 4-fold or greater increases of HAI antibodies in each group against the vaccine.</measure>
    <time_frame>Approximate Days: 1, 3, 7 and 28 after receipt of the first dose of vaccine</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT of neutralizing antibody, proportion of subjects achieving a serum neutralizing antibody titer of 1:40 or greater, and frequency of 4-fold or greater increases of neutralizing antibodies in each group against the subvirion inactivated A/H5N1 virus</measure>
    <time_frame>28 days after receipt of the second dose of vaccine (approximately Day 56).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of HAI antibody, proportion of subjects achieving a serum HAI antibody titer of 1:40 or greater, and frequency of 4-fold or greater increases of HAI antibodies in each group against the subvirion inactivated A/H5N1 virus vaccine</measure>
    <time_frame>28 days after receipt of the second dose of vaccine (approximately Day 56).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Inactivated monovalent influenza A/H5N1 with ASO3 adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be vaccinated with 3.75 micrograms(mcg) of H5N1 hemagglutinin plus AS03 given intramuscularly in two doses 28 days apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactivated monovalent influenza A/H5N1 without ASO3 adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will be vaccinated with 3.75 mcg of H5N1 hemagglutinin alone, given intramuscularly, in two doses 28 days apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASO3 Adjuvant</intervention_name>
    <description>3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.</description>
    <arm_group_label>Inactivated monovalent influenza A/H5N1 with ASO3 adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza A/H5N1 Vaccine</intervention_name>
    <description>3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.</description>
    <arm_group_label>Inactivated monovalent influenza A/H5N1 with ASO3 adjuvant</arm_group_label>
    <arm_group_label>Inactivated monovalent influenza A/H5N1 without ASO3 adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are males or non-pregnant females between the ages of 18 and 49 years, inclusive.&#xD;
&#xD;
          -  Women of childbearing potential (not surgically sterile via tubal ligation, bilateral&#xD;
             oophorectomy or hysterectomy or who are not postmenopausal for &gt;/= 1 year) must agree&#xD;
             to practice adequate contraception (that may include, but is not limited to,&#xD;
             abstinence, monogamous relationship with vasectomized partner, barrier methods such as&#xD;
             condoms or diaphragms with spermicide or foam, intrauterine devices, and licensed&#xD;
             hormonal methods) during the study for at least 30 days following the last&#xD;
             vaccination. Method of contraception will be captured on the appropriate case report&#xD;
             form (CRF).&#xD;
&#xD;
          -  Are in good health, as determined by vital signs (oral temperature, pulse and blood&#xD;
             pressure), medical history and complete physical examination (without genital and&#xD;
             rectal exam) to ensure no existing chronic medical diagnoses or conditions are&#xD;
             present.&#xD;
&#xD;
          -  For women of childbearing potential, negative urine or serum pregnancy test within 24&#xD;
             hours prior to vaccination.&#xD;
&#xD;
          -  Are able to understand and comply with planned study procedures.&#xD;
&#xD;
          -  Provide written informed consent prior to initiation of any study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a known allergy to eggs or other components of the vaccine (including gelatin,&#xD;
             formaldehyde, octoxinol-9, thimerosal and chicken protein), or allergy to&#xD;
             squalene-based adjuvants.&#xD;
&#xD;
          -  Women who are breastfeeding or plan to breastfeed at any given time from the first&#xD;
             vaccination until 30 days after the last vaccination.&#xD;
&#xD;
          -  Have long term use (defined as taken for 2 weeks or more in total at any time during&#xD;
             the past 2 months) of high dose oral or parenteral glucocorticoids (high dose defined&#xD;
             as prednisone &gt;/= 20 mg total daily dose, or equivalent dose of other&#xD;
             glucocorticoids); or high-dose inhaled steroids (high dose defined as &gt;800 mcg/day of&#xD;
             beclomethasone dipropionate or equivalent); or systemic corticosteroids of any dose&#xD;
             within the past 4 weeks.&#xD;
&#xD;
          -  Have immunosuppression as a result of an underlying illness or treatment, or use of&#xD;
             anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36&#xD;
             months.&#xD;
&#xD;
          -  Have an active neoplastic disease or a history of any hematologic malignancy.&#xD;
&#xD;
          -  Have a diagnosis of schizophrenia, bipolar disease, or other major psychiatric&#xD;
             diagnosis.&#xD;
&#xD;
          -  Hospitalized for psychiatric illness, history of suicide attempt, or confinement for&#xD;
             danger to self or others, within the past 10 years.&#xD;
&#xD;
          -  Receiving systemic, prescription medications for the treatment of chronic medical&#xD;
             conditions, unless such use is on a PRN (as needed) basis only. Non-PRN use of&#xD;
             systemic, over-the-counter medications and PRN systemic, prescription medication may&#xD;
             be allowed if, in the opinion of the investigator, they pose no additional risk to&#xD;
             subject safety or assessment of immunogenicity/reactogenicity. Note: Topical, nasal,&#xD;
             and inhaled medications; vitamins; and contraceptives are also permitted.&#xD;
&#xD;
          -  Received pre-medication with analgesic or antipyretic agents in the 6 hours prior to&#xD;
             first vaccination, or planned medication with analgesic or antipyretic in the week&#xD;
             following first vaccination. This criterion should not preclude subjects receiving&#xD;
             such medication if the need arises. However, pre-medication is to be discouraged.&#xD;
&#xD;
          -  Received immunoglobulin or other blood products (with exception of Rho D immune&#xD;
             globulin) within the 3 months prior to the first vaccination.&#xD;
&#xD;
          -  Received any live licensed vaccines within 4 weeks or inactivated licensed vaccines&#xD;
             within 2 weeks prior to the first vaccination or plan receipt of such vaccines within&#xD;
             56 days following the first vaccination. This is inclusive of licensed seasonal&#xD;
             influenza vaccines.&#xD;
&#xD;
          -  Have an acute or chronic medical condition that, in the opinion of the site principal&#xD;
             investigator or appropriate sub-investigator, would render vaccination unsafe, would&#xD;
             interfere with the evaluation of responses or is not generally seen in &quot;normal,&#xD;
             healthy subjects&quot;.&#xD;
&#xD;
          -  Have a history of severe reactions following previous immunization with contemporary&#xD;
             influenza virus vaccines.&#xD;
&#xD;
          -  Have an acute illness, including an oral temperature greater than or equal to 100.4&#xD;
             degree F, within 3 days prior to the first vaccination.&#xD;
&#xD;
          -  Pulse is less than 55 bpm or greater than 100 bpm.&#xD;
&#xD;
          -  Systolic blood pressure is less than 90 mm Hg or greater than 140 mm Hg.&#xD;
&#xD;
          -  Diastolic blood pressure is less than 60 mm Hg or greater than 90 mmHg.&#xD;
&#xD;
          -  Received an experimental agent (vaccine, drug, biologic, device, blood product, or&#xD;
             medication) within 1 month prior to the first vaccination or expects to receive an&#xD;
             experimental agent, other than from participation in this study, during the 14-month&#xD;
             study period.&#xD;
&#xD;
          -  Are participating or plan to participate in another clinical trial with a licensed&#xD;
             product during the 14-month study period.&#xD;
&#xD;
          -  Have any condition that, in the opinion of the site principal investigator or&#xD;
             appropriate sub-investigator, would place the subject at an unacceptable risk of&#xD;
             injury, or render them unable to meet the requirements of the protocol, or confound&#xD;
             the interpretation of results.&#xD;
&#xD;
          -  Participated in an influenza A/H5 vaccine study in the past in a group receiving&#xD;
             vaccine (does not apply to documented placebo recipients) or have a history of A/H5&#xD;
             infection prior to enrollment.&#xD;
&#xD;
          -  Have known active HIV, Hepatitis B, or Hepatitis C infection.&#xD;
&#xD;
          -  Have a history of alcohol or drug abuse in the last 5 years.&#xD;
&#xD;
          -  Plan to travel outside the U.S. in the time between the first vaccination and 56 days&#xD;
             following the first vaccination.&#xD;
&#xD;
          -  Have a history of Guillain-Barr√© Syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2012</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza, vaccine, H5N1, monovalent, adjuvant, ASO3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

